New Delhi: The Supreme Court on Monday asked the center to describe the policy of the revitalization of PSU manufacturing vaccines – many of which were closed during the government upa and where NDA in 2016 promised to revive after modernization – which could play an important role in the manufacture of independent India in the vaccine market Domestic $ 2 billion.
Judge Dy Chandrachud and when Bopanna stepped back from issuing notifications to the Union Government in the PIL submitted by the former Health Secretary during the Vajpayee Government, Amulya Ratna Nanda, and several NGOs, Aishwarya Bhati said that the problem was lifted “down solely in the policy domain executive”.
But the policy barrier submitted by SG does not prevent the bench ask, “We want to know what the union government policy is against the Psus Vaccine Manufacturing?” Mehta said that the center would file a detailed response to PIL and SC posted this problem for further hearing in January.
The Petitioner through Senior Advocate Colin Gonsalves attracted the attention of the court to the pill that submitted in 2009, which has accused “the government of the union and certain ministers in the central cabinet deliberately adulted to public sector and vaccine units with corrupt motives to support private pharmaceutical companies.
The thin reason given by the United States of the trial is that PSU is not in accordance with manufacturing practices (GMP).
“” This step in the Covid-19 vaccine case (Covaxin produced by private company Bharat Biotech International Private Ltd) Basically it has resulted in public payments Twice for vaccines; private companies take margins from public sector manufacturing for final products, after having taken government grants to develop products and infrastructure needed to make it, “the Petitioner said, while remaining silent on vaccine production by the Indian Serum Institute.
The request said three PSUS – Bharat Imunological and Biological, Bulandshahr; Haffin biopharmaceuticals, Mumbai; And Indian Immunology, Hyderabad – Recently chosen to produce Covaxin, making this PSU contract manufacturer for the private sector because of a defective policy on making vaccines by the trade union government.
Speaking of this problem, the previous officials said that it was a central effort that resulted in the PSU which was removed to increase the production of covaxin in the middle of a pandemic.
Gonsalves said GMP standards must be filled with export objectives and not for local consumption.
“Minister of Wife (Health) at the time (UPA government) wife had established a vaccine park in Chennai to import vaccines while her husband was busy sarifing the PSU so that the competition would be eliminated.”